Next Article in Journal
Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain
Next Article in Special Issue
Personalized [177Lu]Lutetium-PSMA Therapy for Patients with Pre-Treated Castration-Resistant Prostate Cancer: A Single Institution Experience from a Comprehensive Cancer Centre
Previous Article in Journal
Recent Advancement in Breast Cancer Research: Insights from Model Organisms—Mouse Models to Zebrafish
Previous Article in Special Issue
High-Frequency Pulsed Electric Field Ablation in Beagle Model for Treatment of Prostate Cancer
 
 
Review
Peer-Review Record

Treating Primary Node-Positive Prostate Cancer: A Scoping Review of Available Treatment Options

Cancers 2023, 15(11), 2962; https://doi.org/10.3390/cancers15112962
by Lotte G. Zuur 1, Hilda A. de Barros 1, Koen J. C. van der Mijn 2, André N. Vis 3, Andries M. Bergman 2, Floris J. Pos 4, Jeroen A. van Moorselaar 3, Henk G. van der Poel 1,3, Wouter V. Vogel 4,5 and Pim J. van Leeuwen 1,*
Reviewer 1:
Reviewer 2:
Cancers 2023, 15(11), 2962; https://doi.org/10.3390/cancers15112962
Submission received: 8 May 2023 / Revised: 23 May 2023 / Accepted: 24 May 2023 / Published: 29 May 2023
(This article belongs to the Special Issue Prostate Cancer Therapy)

Round 1

Reviewer 1 Report

English language should be improved in bothgrammar and syntax

 

Lines 144-147 refer to ADT therapy in associationwith surgical therapy and radiotherapyreaching the conclusion that the association of one or the otherdoes not give statistically significant differencesHowever, the age of the patients undergoing the treatments is not reportedtherefore I suggest thatyou investigate this aspect further

 

Paragraph 3.2.4 at line 231 discusses the use of docetaxel chemotherapy as an adjuvantat thisregart i suggest the following articlehttps://pubmed.ncbi.nlm.nih.gov/32474391/

 

It is possible to analyze the comorbidities of patientswith prostate cancer to understand whether they act as protective factors or risk factors for the progression of oncological disease in patients whoundergo ADT. At this regard the following articlecould be interestinghttps://pubmed.ncbi.nlm.nih.gov/32570240/

Minor revisions

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

Nice review for patients with cN1/pN1 prostate cancer; Gives the reader an overview about potential treatment options. However, I missed a conclussion and recommendation which treatment would be best for the patient. Moreover, due to the introduction of new drugs like apalutamide, duralutamide in the course of treatment and modern diagnostic procederures like PSMA PET scan, a change and update in treatment options must be assumed in the near future.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Round 2

Reviewer 1 Report

Authors answered all comments and suggestions.

Minor revisions.

Reviewer 2 Report

I am fine with the revised manuscript

Back to TopTop